Nordea: Short-term doubts about the Novo share
The pan-Nordic bank Nordea says there are some insecurities and doubts surrounding Novo Nordisk in the next couple of months that could affect the share price – which there is one overriding reason for.
BY BENJAMIN WERNER CHRISTENSEN
There is a very good chance that the preliminary data from Novo Nordisk’s cardiovascular study with Tresiba are strong enough to allow the Danish group to submit an application to the FDA, but lingering insecurities about that very scenario can cause short-term fluctuations in the share price, according to Nordea’s chief strategist, Bjarne Breinholt Thomsen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s handpicked dozen to decide Tresiba’s fate
For abonnenter
EMA recommends Tresiba for children
For abonnenter
“Novo is more dependent on Tresiba than ever”
For abonnenter
